ELAN vs. UTHR: Elanco Animal Health vs. United Therapeutics Stock Comparison

Company Profile

Elanco Animal Health (ELAN) and United Therapeutics (UTHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ELAN is classified in Pharmaceuticals while UTHR is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Elanco Animal Health (ELAN) has an aggressive beta of 1.65, indicating higher sensitivity to broad-market moves, while United Therapeutics (UTHR) is defensive at 0.49 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: United Therapeutics (UTHR) earns 19.13% on shareholders’ equity, ranked against its industry; Elanco Animal Health (ELAN) has no ROE this period.

Elanco Animal Health (ELAN) reports a negative net margin of -2.86%, usually indicating a net loss over the period. Meanwhile United Therapeutics (UTHR) reports 38.61%, ranking against industry peers normally.

United Therapeutics (UTHR) at 28.99% operates in the top operating margin quartile, ahead of Elanco Animal Health (ELAN) at 6.64%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Elanco Animal Health (ELAN) at 6.22% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

United Therapeutics (UTHR) at 13.07% is around its peer norm for EPS growth, while Elanco Animal Health (ELAN) at -169.12% drops into the bottom quartile, signaling weaker earnings momentum.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: United Therapeutics (UTHR) shows current ratio of 4.61 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.

Only one side’s leverage can be read here: Elanco Animal Health (ELAN) carries debt-to-equity ratio of 0.64 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

Financial Strength Metrics

Dividends

Neither Elanco Animal Health (ELAN) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Elanco Animal Health (ELAN) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: United Therapeutics (UTHR) trades at 21.22 times trailing earnings, ranked against its peers, while Elanco Animal Health (ELAN) has no P/E ratio this period.

Elanco Animal Health (ELAN) at 2.50 sits in the cheaper P/S ratio quartile while United Therapeutics (UTHR) at 7.51 prices around its industry’s middle — ELAN costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Elanco Animal Health (ELAN) at 1.95 and United Therapeutics (UTHR) at 3.80 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics